Letter to the EditorEnzyme replacement therapy in Fabry disease: Towards a better understanding of the implications of antibody formation and dose
References (23)
- et al.
Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta
Mol. Genet. Metab.
(2008) - et al.
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3
Mol. Genet. Metab.
(2008) - et al.
Enzyme therapy for Fabry disease: neutralizing antibodies towards agalsidase alpha and beta
Kidney Int.
(2004) - et al.
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
Mol. Genet. Metab.
(2007) - et al.
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease
Genet. Med.
(2007) - et al.
Recombinant enzyme therapy for Fabry disease. Absence of editing of human ‡-Galactosidase A mRNA
Am. J. Hum. Gen.
(2003) - et al.
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study
Am. J. Cardiol.
(1987) - et al.
Clinical benefit of enzyme replacement therapy in Fabry disease
Kidney Int.
(2006) - et al.
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy
Am. J. Cardiol.
(2006) - et al.
Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease
Mol. Genet. Metab.
(2008)
Monitoring enzyme replacement therapy in Fabry disease—role of urine globotriaosylceramide
J. Inherit. Metab. Dis.
(2005)
Cited by (3)
Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion
2018, Journal of Allergy and Clinical ImmunologyThe treatment for Fabry disease: Focus on agalsidase alpha and beta
2021, Recenti Progressi in MedicinaEnzyme replacement therapy for Fabry disease: some answers but more questions
2011, Therapeutics and Clinical Risk Management
Copyright © 2008 Elsevier Inc. All rights reserved.